{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T03:48:20Z","timestamp":1788666500941,"version":"build-2803163510"},"reference-count":136,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Lung cancer remains the leading cause of cancer-related mortality worldwide. Although small cell lung cancer (SCLC) accounts for a smaller percentage of lung cancer cases, it has remained a significant contributor to the overall mortality burden because of its inherently aggressive nature. Over several years, and until recently, there have been no major breakthroughs in the management of SCLC. Concurrent chemoradiation with platinum doublet chemotherapy has remained the mainstay of treatment in limited-stage disease, with chemotherapy being the main and only treatment in extensive stage. Despite having an initial good response to those treatments in most patients, progression of cancer has been nearly inevitable, with no additional effective therapeutic options, and the majority of patients with SCLC dying of their disease. Fortunately, the last decade has witnessed some major scientific advances addressing the huge unmet needs in the realm of SCLC management and ushered in renewed hope in the lung cancer community. From approval of immune checkpoint inhibitors and lurbinectedin, a newer chemotherapy agent, to novel immunotherapies such as tarlatamab, a DLL3-CD3 bispecific T-cell engager, and other upcoming promising drugs, the therapeutic armamentarium for SCLC is steadily expanding. In this study, we review the current landscape of both systemic therapy as well as radiation therapy for SCLC, with a focus on major developments over the past decade, current standards of care, and novel therapeutics that are expected to revolutionize the treatment of this aggressive malignancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/edbk-26-524964","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T19:59:11Z","timestamp":1780430351000},"source":"Crossref","is-referenced-by-count":2,"title":["Updates in Small Cell Lung Cancer Treatment: No Longer Too Small to Ignore\u2014A Review of Recent Therapeutic Advances"],"prefix":"10.1200","volume":"46","author":[{"given":"Yajur","family":"Arya","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Dyer","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Center, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Hegi-Johnson","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Center, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Reguart","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Thoracic Oncology Unit, August Pi Sunyer Biomedical Research Institute (IDIBAPS), Hospital Clinic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9142-4113","authenticated-orcid":true,"given":"Rami","family":"Manochakian","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_2_2_2","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel RL","year":"2026","unstructured":"Siegel RL, Kratzer TB, Wagle NS, et al: Cancer statistics, 2026. CA Cancer J Clin 76:e70043, 2026","journal-title":"CA Cancer J Clin"},{"key":"e_1_3_2_3_2","volume-title":"An interactive website for SEER cancer statistics. Surveillance Research Program","author":"SEER*Explorer","year":"2025","unstructured":"SEER*Explorer: An interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute, 2025"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0560"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.02.011"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108085"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2011.03.002"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0133-9"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.07.008"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.12.014"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.01.010"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_432524"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29098"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-023-03216-3"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.04.021"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.09.43"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404873"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.0035"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107924"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100408"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.03.008"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.16464"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00224-8"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-472794"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0753-2"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01011-6"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30068-1"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1656502"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0745-2"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30565-4"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.02.009"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2845"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307980"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00553"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.057"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502099"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2025.03.006"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35738"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00480-2"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.3368"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.371"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00363"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.3370"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS8128"},{"key":"e_1_3_2_47_2","volume-title":"An Open-label, Phase 1 Study of QLS31904 as Monotherapy to Assess the Safety, Tolerability and PK in Patients With Advanced Solid Tumors","year":"2022","unstructured":"An Open-label, Phase 1 Study of QLS31904 as Monotherapy to Assess the Safety, Tolerability and PK in Patients With Advanced Solid Tumors. 2022."},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.074"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.10.013"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.8007"},{"key":"e_1_3_2_51_2","volume-title":"An Open-Label, Multicenter Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of RO7616789 in Participants With Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas","year":"2022","unstructured":"An Open-Label, Multicenter Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of RO7616789 in Participants With Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas, 2022"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02012-z"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.3369"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0061"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-23-0524"},{"key":"e_1_3_2_56_2","volume-title":"A Phase I Dose Escalation Study of Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by a Phase II Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer","year":"2024","unstructured":"A Phase I Dose Escalation Study of Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by a Phase II Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer, 2024"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.8001"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1880"},{"key":"e_1_3_2_59_2","volume-title":"A Phase II, Multi-site, Open-label, Parallel Group Trial of BNT327 in Combination With Chemotherapy for Participants With Untreated Extensive-stage Small-cell Lung Cancer and Participants With Previously Treated Small-cell Lung Cancer","year":"2024","unstructured":"A Phase II, Multi-site, Open-label, Parallel Group Trial of BNT327 in Combination With Chemotherapy for Participants With Untreated Extensive-stage Small-cell Lung Cancer and Participants With Previously Treated Small-cell Lung Cancer, 2024"},{"key":"e_1_3_2_60_2","volume-title":"A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide\/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide\/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer","year":"2024","unstructured":"A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide\/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide\/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer, Bristol-Myers S, 2024"},{"key":"e_1_3_2_61_2","volume-title":"A Phase II Clinical Study of Ivonescimab Combination Therapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)","year":"2025","unstructured":"A Phase II Clinical Study of Ivonescimab Combination Therapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC), 2025"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-025-01655-5"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2026.103091"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.70178"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02142"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2026.02.006"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03600-2"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.10.078"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.047"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.12.028"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.049"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.3041"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.046"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.3002"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0540-1"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0554"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02487"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1876"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2565995"},{"key":"e_1_3_2_80_2","volume-title":"A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With YL201 With or Without Anti-PD-L1 in Subjects With Extensive Stage Small Cell Lung Cancer","year":"2025","unstructured":"A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With YL201 With or Without Anti-PD-L1 in Subjects With Extensive Stage Small Cell Lung Cancer, MediLink, 2025"},{"key":"e_1_3_2_81_2","unstructured":"Plieth J: Another B7-H3 death puts Imdelltra combo in trouble. ApexOnco Oncology Pipeline 2026. https:\/\/www.oncologypipeline.com\/apexonco\/another-b7-h3-death-puts-imdelltra-combo-trouble"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3321"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.005"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132256"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.1095"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-2090"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.105"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.3001"},{"key":"e_1_3_2_90_2","volume-title":"A Phase 2 Randomized, Open Label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Subjects With Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)","year":"2025","unstructured":"A Phase 2 Randomized, Open Label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Subjects With Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC), 2025"},{"key":"e_1_3_2_91_2","volume-title":"ARTEMIS-008: A Multicenter, Randomized, Open-label, Phase 3 Study of HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy","year":"2024","unstructured":"ARTEMIS-008: A Multicenter, Randomized, Open-label, Phase 3 Study of HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy, 2024"},{"key":"e_1_3_2_92_2","volume-title":"A Multicenter, Randomized, Controlled, Open-label, Phase III Study to Compare the Efficacy and Safety of YL201 Versus Topotecan Hydrochloride in Subjects with Relapsed Small Cell Lung Cancer","year":"2024","unstructured":"A Multicenter, Randomized, Controlled, Open-label, Phase III Study to Compare the Efficacy and Safety of YL201 Versus Topotecan Hydrochloride in Subjects with Relapsed Small Cell Lung Cancer, 2024"},{"key":"e_1_3_2_93_2","volume-title":"A Phase 3, Multicenter, Randomized, Open-label Study of MHB088C for Injection Versus Treatment of Physician's Choice (TPC) in Comparing the Efficacy and Safety in Subjects With Relapsed Small Cell Lung Cancer (SCLC)","year":"2025","unstructured":"A Phase 3, Multicenter, Randomized, Open-label Study of MHB088C for Injection Versus Treatment of Physician's Choice (TPC) in Comparing the Efficacy and Safety in Subjects With Relapsed Small Cell Lung Cancer (SCLC), 2025"},{"key":"e_1_3_2_94_2","volume-title":"A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer After Failure of Anti-PD-1\/PD-L1 Monoclonal Antibodies and Platinum-based Chemotherapy","year":"2024","unstructured":"A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer After Failure of Anti-PD-1\/PD-L1 Monoclonal Antibodies and Platinum-based Chemotherapy, Baili-Bio Pharmaceutical Co L, 2024"},{"key":"e_1_3_2_95_2","volume-title":"A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants With Relapsed Small Cell Lung Cancer","year":"2025","unstructured":"A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants With Relapsed Small Cell Lung Cancer, Zai Lab LLC, 2025"},{"key":"e_1_3_2_96_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268200"},{"key":"e_1_3_2_97_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"e_1_3_2_98_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"e_1_3_2_99_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0299"},{"key":"e_1_3_2_100_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1533"},{"key":"e_1_3_2_101_2","volume-title":"Characterizing the Theranostic Potential of DLL3-targeting Agents in High-grade Neuroendocrine Carcinomas of the Lung and Prostate","year":"2025","unstructured":"Characterizing the Theranostic Potential of DLL3-targeting Agents in High-grade Neuroendocrine Carcinomas of the Lung and Prostate, 2025"},{"key":"e_1_3_2_102_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-CT107"},{"key":"e_1_3_2_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.03.019"},{"key":"e_1_3_2_104_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2346"},{"key":"e_1_3_2_105_2","first-page":"A727","article-title":"697 A phase 1 study of AMG 119, a DLL3-targeting, chimeric antigen receptor (CAR) T cell therapy, in relapsed\/refractory small cell lung cancer (SCLC)","volume":"10","author":"Byers L","year":"2022","unstructured":"Byers L, Heymach J, Gibbons D, et al. 697 A phase 1 study of AMG 119, a DLL3-targeting, chimeric antigen receptor (CAR) T cell therapy, in relapsed\/refractory small cell lung cancer (SCLC). J ImmunoTherapy Cancer. 2022;10:A727.","journal-title":"J ImmunoTherapy Cancer"},{"key":"e_1_3_2_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.10.041"},{"key":"e_1_3_2_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2017.03.009"},{"key":"e_1_3_2_108_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.10.020"},{"key":"e_1_3_2_109_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30439-4"},{"key":"e_1_3_2_110_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901283400403"},{"key":"e_1_3_2_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30318-2"},{"key":"e_1_3_2_112_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01359"},{"key":"e_1_3_2_113_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.08.007"},{"key":"e_1_3_2_114_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.04.007"},{"key":"e_1_3_2_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00189-9"},{"key":"e_1_3_2_116_2","unstructured":"Novello S Cheng Y Spigel D et al: Patient-reported outcomes with consolidation durvalumab versus placebo following concurrent chemoradiotherapy in limited-stage small-cell lung cancer: Results from the phase 3 ADRIATIC trial. J Thorac Oncol 10.1016\/j.jtho.2026.103564 [epub ahead of print on January 30 2026]"},{"key":"e_1_3_2_117_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01569"},{"key":"e_1_3_2_118_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.09.010"},{"key":"e_1_3_2_119_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.03.034"},{"key":"e_1_3_2_120_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61085-0"},{"key":"e_1_3_2_121_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2020.02.009"},{"key":"e_1_3_2_122_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01055"},{"key":"e_1_3_2_123_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.09.003"},{"key":"e_1_3_2_124_2","volume-title":"RAndomized Phase II\/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial","year":"2020","unstructured":"RAndomized Phase II\/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial, Oncology NRG, 2020"},{"key":"e_1_3_2_125_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2017.07.019"},{"key":"e_1_3_2_126_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199908123410703"},{"key":"e_1_3_2_127_2","doi-asserted-by":"publisher","DOI":"10.7150\/jca.21465"},{"key":"e_1_3_2_128_2","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Small Cell Lung Cancer V.2.2026. \u00a9National Comprehensive Cancer Network Inc. 2026. All rights reserved. To view the most recent and complete version of the guideline go online to https:\/\/www.nccn.org"},{"key":"e_1_3_2_129_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30230-9"},{"key":"e_1_3_2_130_2","volume-title":"MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)","year":"2019","unstructured":"MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK), National Cancer I, 2019"},{"key":"e_1_3_2_131_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.05.013"},{"key":"e_1_3_2_132_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00639"},{"key":"e_1_3_2_133_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/not114"},{"key":"e_1_3_2_134_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.1271"},{"key":"e_1_3_2_135_2","volume-title":"Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Brain Metastases From Small Cell Lung Cancer","year":"2021","unstructured":"Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Brain Metastases From Small Cell Lung Cancer, National Cancer I, 2021"},{"key":"e_1_3_2_136_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02823"},{"key":"e_1_3_2_137_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2026.01.007"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-26-524964","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T19:59:24Z","timestamp":1780430364000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-26-524964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":136,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1200\/EDBK-26-524964"],"URL":"https:\/\/doi.org\/10.1200\/edbk-26-524964","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"e524964"}}